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1. Introduction 
Despite the proven the efficacy of antipsychotic drugs approximately 10-30% of all 
schizophrenic patients show poor response or remain resistant to antipsychotic medications, 
and up to an additional 30% of patients have partial responses to treatment, meaning that 
they exhibit improvement in psychopathology but continue to have mild to severe 
symptoms (Barnes, 2011; Miyamoto et al., 2005). The proportion considered to be ‘treatment 
resistant’ varies according to the criteria used (Barnes et al., 2003; Barnes, 2011: Conley and 
Kelly, 2001; Pantelis and Lambert, 2003).  A minority (around 10%) of patients receiving 
conventional or atypical antipsychotics do not achieve remission even after the first episode 
(Crow et al., 1986; Lambert et al., 2008). More commonly, treatment resistance develops as 
the illness becomes progressively more unresponsive to medication (Barnes 2011; Wiersma 
et al., 1998). Kane et al. (1988) defined treatment refractoriness as lack of periods of good 
functioning for 5 years, no response to two different classes of neuroleptics and presence of 
moderate to severe symptomatology including positive and negative symptoms, as well as 
disorganized or violent/aggressive behaviour, thought disorder and suicidal ideation. 
Predictors associated with an unfavourable response to treatment are cognitive functioning 
deficits (Rabinowitz et al., 2000), poor premorbid functioning (Crespo-Facorro et al., 2007; 
Duñó et al., 2008), earlier age of onset (Gogtay et al., 2011), duration of untreated psychosis 
(Farooq et al., 2009) and male gender (Caspi et al., 2007). It remains uncertain whether 
treatment resistant schizophrenia should be considered simply as the more severe end of the 
illness spectrum or as a distinct subtype of schizophrenia for which neurocognitive markers 
of resistance should be explored (Barnes, 2011).  
Social cognition generally refers to mental operations that underlie human transactions, 
including perceiving and interpreting social stimuli as well as responding to socially 
relevant inputs, such as dealing with intentions and behaviours of others. Theory of Mind 
(ToM) or mentalizing, a subdomain of social cognition, is defined as the ability to think 
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about people in terms of their mental states (Green et al., 2008a). The bulk of evidence has 
shown consistent social cognitive impairments in schizophrenia (Green et al.,2008b), that 
can be present at early phases (Brüne et al., 2011; Chung et al., 2008; Couture et al., 2008) and 
persist trough different phases of the illness (Green et al., 2011), and several reviews and 
meta-analysis have established that patient-control differences on mentalizing skills are 
large and persistent across the chronic phase of illness (Bora et al., 2009; Brüne 2005).   
Clozapine is the only antipsychotic that has been found to show superior efficacy for 
treatment-resistant patients when compared to conventional and atypical antipsychotic 
drugs. Clozapine is the most effective antipsychotic for severe refractory schizophrenia 
(approximately 30-60% of patients who fail to respond to other antipsychotics may respond 
to clozapine), and moderately refractory illness (Barnes, 2011), Further, there are other 
important benefits with clozapine, including improvement in cognitive function (Bilder et 
al., 2002; Machado de Sousa and Hallak, 2002; Purdon et al., 2001), reduction in suicidality 
(Meltzer et al., 2003) and an anti-hostility action or improvement in persistent aggression 
and behavioural disturbance (Krakowski et al., 2006; Volavka and Citrome, 2008; Volavka et 
al., 2004). Despite of the abundance of findings about social cognitive deficits in 
schizophrenia, only a few reports have related these handicaps to the clinical improvement 
obtained with antipsychotic treatment. Mizrahi et al. (2007) and Harvey et al. (2006) offered 
some evidence that the atypical risperidone and olanzapine enhanced performance on 
particular social cognition abilities (Kee et at., 1998; Littrel et al., 2004). Accordingly, Savina 
and Beninger (2007) found that olanzapine and clozapine but not typical neuroleptics or 
risperidone may either improve ToM ability or protect against its decline, probably by 
restoring or improving neural activation at the mPFC. Another study in the same line 
carried out by Lund et al. (2002) cohered with these results. Contrary to that, Sergi et al. 
(2007) and Penn et al. (2009) found no differences among medications or within each 
medication group over time, on these measures. In remitted schizophrenics anomalies in 
social cognition were worse in the more severe patients (Sprong et al., 2007) and some of the 
abovementioned studies reported reductions of social cognitive dysfunctions with a specific 
antipsychotic drug. In this context, the present study attempted to determine which 
pharmacological treatment (conventional, atypical antipsychotics or clozapine) exhibited 
superior efficacy to improve ToM skills and whether the deficits on ToM might be linked 
with resistance to antipsychotic treatment in stable schizophrenic patients. Given that 
abnormalities in mentalizing are particularly severe in patients with poor premorbid 
adjustment (Duñó et al., 2008), and that poor premorbid adjustment is considered a factor of 
refractoriness to treatment, we expected to find a link between the degree of ToM deficit and 
an increased risk of antipsychotic drug resistance. 
2. Method 
Fifty-eight schizophrenic patients fulfilling diagnostic and statistical manual (DSM) IV 
criteria were recruited in a consecutive fashion during the years 2001–2005. Subjects who 
did not give their consent to participate and those with a visual or auditory disability 
limiting test application, neurological disease, or another chronic/acute condition that could 
interfere with cognitive performance were not recruited. Patients with additional DSM-IV 
diagnosis on Axis I/II were also not recruited. Participants showing an IQ below 70 (Blyler 
et al., 2000) were excluded from the study. All subjects were on clinical remission at 5 
months after discharge from the Day Hospital of the Psychiatry Unit, Parc Taulí University 
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Hospital (Sabadell-Barcelona, Spain). Clozapine treatment was prescribed only to patients 
who met the criteria for antipsychotic treatment resistance (Kane et al., 1988).   
The schizophrenic group was compared to a control group of forty-eight patients with no 
psychiatric diagnosis who had been admitted to the Orthopedics and Surgery Department 
of the same hospital. Control subjects were recruited at the same time as the group with 
schizophrenia and were matched by sex, age and educational level. The exclusion criteria 
for this group included a history of psychiatric disorders, the presence of psychopathology 
and distress at the time of the evaluation according to the three global indices of the 
Symptom Checklist-90-Revised scale (SCL-90-R) (Positive Symptom Total, Global Severity 
Index, Positive Symptom Distress Index) (Martinez-Azumendi et al., 2001) medical 
prescription of psychoactive drugs and an IQ score below 70 (Blyler et al., 2000). 
Sociodemographic factors of this group are described in Table 1.  
2.1 Assessment 
Patient’s symptom severity was assessed with the positive and negative syndrome scale 
(PANSS) (Kay et al., 1987). Premorbid adjustment with the Premorbid Adjustment Scale 
(PAS) (Cannon-spoor et al., 1982; Silverstein et al., 2002). Four false belief ToM tasks were 
applied: two first-order tasks, “the cigarettes” (Happé, 1994) and “Sally and Anne” (Baron-
Cohen, 1989) and two second-order tasks, “the burglar” (Happé and Frith, 1994) and “the 
ice-cream van” (Baron-Cohen et al., 1985). Stories were read aloud by the examiner and 
subjects had to listen and answer two questions. The first one (a ToM question) had to be 
answered on the basis of the mental state of one of the characters and concerned that 
character’s false belief within the situation. The second one (control question) reflected the 
subject’s comprehension of the story. These tasks were rated according to the following:  
 correct ToM (task score = 1):  correct answers in both ToM and control questions;  
 ToM deficit (task score = 0): failure in ToM question and correct answer in control 
question;  
 comprehension error: correct answer in ToM question and failure in control question or 
failure in both (data in this category omitted from the analysis).   
Patients were excluded from the study if they showed comprehension errors in more than 
two ToM tasks. If the comprehension error was in a second-order ToM task, none of the 
second-order ToM tasks were considered for analysis, while first-order ones were. The same 
criteria were applied when comprehension errors appeared in first-order ToM 
tasks. Subsequently, three categorical subgroups of ToM performance were established for 
both first- and second-order tasks by adding up scores as follows: 0=two tasks with scores of 
0 (severe ToM deficit); 1=one task scoring 1 and the other scoring 0 (low ToM performance); 
2=scoring of 1 in both tasks (good ToM performance).  Neurocognitive measures were 
grouped into several domains, from basic to high-level processing according to 
Nuechterlien et al. (2004) criteria: Speed processing (Trail Making Test A (TMT-A) (Reitan, 
1993), Working Memory (Digit Span Backward) (Wechsler, 1999), Executive functions 
(Stroop Color-Word (Golden, 1994), Trail Making Test B [TMT-B] (Reitan, 1993), Block 
Design (Wechsler, 1999).  
Antipsychotic treatment included 3 groups of drugs: conventional, atypical (olanzapine, 
risperidone aripiprazol) and clozapine. Drug doses for each group were converted to 
haloperidol equivalents (mg/day). Patients were assessed on these all measures at 5 months 
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after discharge from hospital, except PANSS scale, which was further administrated at start 
and end of hospitalization.     
Long-term Follow-up: 6-10 years later these patients were contacted again through 
telephone calls. All were retraced except 3 who were dead, 4 who had changed address and 
2 who were hospitalized. From the remaining, 21 patients refused to collaborate and 24 
accepted and were re-examined. Symptom severity was assessed with the positive and 
negative syndrome scale (PANSS) (Kay et al., 1987) and ToM tasks were assessed applying 
the same tasks and methodology as stated above.  
2.2 Statistical analysis 
Socio-demographic data as well as neuropsychology and social cognition measures were 
compared in patients and controls by means of either the X2-test (for categorical variables) or 
t-tests. Relations among antipsychotic treatment and haloperidol equivalents doses with 
PANSS scale were studied through descriptive analysis. Comparative analysis between 
social cognition and dosage of haloperidol equivalents were carried out through U Mann-
Whitney tests. Relations between first- and second-order ToM tasks scores and antipsychotic 
treatment were studied by the X2-tests. Ordinal regression models were employed to 
analyze the association between the results of first-order and second-order ToM tasks with 
socio-demographic variables, premorbid adjustment, neuropsychological scores and 
antipsychotic treatment as possible explanatory variables of treatment resistance. Starting 
with regression models including gender and PAS for social isolation, further explanatory 
variables were included if they significantly improved the model fit and yielded maximum 
R-square values. Several links for ordinal regression models were considered and those that 
yielded maximum R-square values were chosen. Finally, it was proved that the models for 
first- and second-order ToM tasks held the assumption of parallel lines (Chen and Meharry, 
2004). Statistical analysis was performed with the statistical software packages SPSS, version 
PASW 18 version 18.0.0 and R, v. 2.11.1, in particular using the contributed package “exact 
RankTests” (Hothorn and Hornik, 2011). P-values below 0.05 were considered statistically 
significant. For the long term follow-up measures only a descriptive analysis was carried 
out.  
3. Results  
Sociodemographic and clinical data of schizophrenic patients and controls are shown in 
Table 1, as well as, neuropsychological and social cognition measures in Table 2. Clear 
differences between patients and controls appeared in independence, paternity and 
occupational status. Premorbid adjustment in the patients was poor, worsening from 
childhood into late adolescence. Patients scored significantly lower in Trail Making Test A, 
Stroop word-colour and Trail Making Test B. Table 3 displays changes over  time in PANSS 
scale in relation to antipsychotic drugs and dosage haloperidol equivalents at discharge and 
follow-up study. Total PANSS scores improved over time in all groups. Patients on 
clozapine had higher scores at each PANSS subscales at baseline and lesser scores at the end 
of assessment. At the long-term follow-up these scores in general decreased slightly, being 
more pronounced for atypical and clozapine. First- and second-order ToM tasks 
performance relations to mean dosage of haloperidol equivalents are shown in Table 4. 
Dosage haloperidol equivalents were inferior in category 2 on both measures. 
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Schizophrenia 
group (N=58) 
Control group 
(N=48) 
p-value 
Males 41 (70.7%) 36 (75.0%)  
Age 31.4 (8.1) 33.9 (8.6)  
Years of education =< 8 years 42 (72.4%) 37 (77.1%)  
Living with own family 15 (25.9%) 35 (72.9%) 
2=23.336; 
p<0.001 
Children 8 (13.8%) 26 (54.2%) 
2=19.650; 
p<0.001 
Employed 12 (20.7%) 41 (85.4%) 
2=44.014; 
p<0.001 
Age of illness onset 21.6 (4.9)   
Psychiatric diagnosis (DSM-IV) 
  Paranoid schizophrenia 
   Non-paranoid schizophrenia 
   Schizofreniform disorder 
   Schizoaffective disorder 
 
39 (67.2%) 
8 (13.7%) 
6 (10.3%) 
5 (8.6%) 
  
Global activity (DSM-IV) 61.6 (11.7)   
SCL-90-R1 
  Positive Symptom Total 
   Global Severity Index 
   Positive Symptom Distress Index 
 
 
 
24.9 (11.2) 
0.27 (0.12) 
1.19 (0.20) 
 
PAS 
  Childhood 
   Early adolescence 
   Late adolescence 
0.27 (0.2) 
0.39 (0.2) 
0.44 (0.2) 
  
Years of illness evolution 9.6 (7.7)   
Drugs    
   Mean dose haloperidol equivalents 
   (mg/day) 
8.7 (7.3)   
   Conventional antipsychotic 14 (24.1%)   
   Atypical antipsychotic 35 (60.3%)   
   Mixed antipsychotic 6 (10.3%)   
   Clozapine2 17 (29.3%)   
   None3 3 (5.2%)   
   Anticholinergic 8 (13.8%)   
   Antidepressant 15 (25.9%)   
Results are presented as mean (standard deviation) in case of continuous variables and as frequency (%) 
in case of categorical variables. Gender, age, and educational level were matching variables; hence, no 
statistical tests for comparison are applied. 
1 Mean normative values: Positive Symptom Total, 25.32 (SD: 14.3); Global Severity Index, 0.51 (0.36); 
Positive Symptom Distress Index, 1.75 (0.48).   
2 Patients on clozapine from the total 35 on atypical antipsychotics. 
3 At evaluation, 5 months after discharge.   
DSM-IV-Diagnostic and Statistical Manual Disorders, Fourth Edition; 
SCL-90-R-Symptom Checlist-90-Revised; PANSS=Positive and Negative Syndrome Scale. 
Table 1. Sociodemographic and clinical characteristics of study cohort 
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Figure 1a and 1b display relations between antipsychotic drugs and performance of first-order 
ToM tasks at discharge and follow-up respectively: 78.6% of patients performed correctly at 
discharge, with a slight non-significant advantage for atypical drugs, whereas 83% performed 
right, with a moderate advantage for clozapine at follow-up. Figure 2a and 2b display 
antipsychotic drugs and performance of second-order ToM tasks at discharge and follow-up: 
63.9% of patients performed correctly at discharge, with a slight non-significant advantage for 
atypical drugs, whereas 79.2% performed right, with moderate advantage for clozapine at 
follow-up study. Tables 5a and 5b show the variables included in the ordinal regression 
models for first- and second-order ToM tasks, respectively. The negative sign of the regression 
coefficients corresponding to premorbid adjustment (PAS social isolation) in both models 
indicates a negative relationship between that variable and the outcome. That is, ordinal 
regression analysis revealed a main association between deficits in first-order and second-
order ToM tasks both with poor social premorbid adjustment (social isolation). In first-order 
ToM tasks, deficits were also related to poor performance on Trail Making Test B. The test 
showed the highest significant association between second-order ToM tasks with block design, 
males and clozapine treatment. R-square values amounted to 0,300 and 0.657, respectively. No 
association was found between first-order ToM tasks with variables of treatment resistance, 
whereas second-order ToM tasks deficits were linked to factors of unfavourable response to 
treatment.  
 
 
Schizophrenia 
group (N=58) 
Control group 
(N=48) 
p-value 
Neuropsychological  measures 
General cognition abilities 
    Intelligence Quotient 
 
96.8 (19.2) 
 
104.1(19.5) 
 
t=-1.918: p=0.060 
Speed of processing 
    Trail Making Test A 
 
43.1 (16.8) 
 
30.9(10.1) 
 
t=4.333; p=0.000 
 Working Memory 
     Digit span backward 
 
5.5 (1.1.9) 
 
5.3(1.7) 
 
t=0.708 p=0.481 
Executive function 
     Stroop word color 
     Trail Making Test B 
     Block design 
 
36.1 (11.2) 
106.9 (51.9) 
40.6 (11.9) 
 
42.3 (10.7) 
84.8 (27.3) 
44.1 (11.6) 
 
t=-2833; p=0.006 
t= 2.829;  p=0.01 
t=-1504; p=0.136 
Social cognition measures 
ToM category 
     First order 
         0 
         1 
         2 
     Second order 
         0 
         1 
         2 
 
11.8% 
11.8% 
76.5% 
 
11.5% 
26.9% 
61.5% 
 
0% 
0% 
100% 
 
4.% 
10.6% 
85.1% 

2=12602; p=0.002 
 
 
 
2=6917; p=0.031 
Results are presented as mean (standard deviation) in case of continuous variables and as frequency (%) 
in case of categorical variables 
Table 2. Neuropsychology and social cognition measures of study cohort 
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PANSS  Conventional     Atypical     Clozapine 
POSITIVE 
Main measures                    
 
Hospitalization starts 
Hospitalization ends 
5 month after discharge 
 
         
 
 
        20.9(4.9)      
        13.8(3.9) 
        12.0(3.9) 
        
 
 
         15.2(7.2)    
         10.5(4.7)     
         10.2(3.7) 
        
 
 
         22.8 (6.6)    
         13.1 (4.1)    
         13.7 (4.3) 
Follow-up                                     12.8(3.9)          10.6(3.1)          10.6(4.9) 
NEGATIVE 
Main measures                      
 
 Hospitalization starts 
 Hospitalization ends 
 5 month after discharge  
 
 
 
 
       21.9(9.5)    
       13.8(4.0) 
       18.5(7.4)             
 
 
 
         28.7(10.4)   
         10.5(4.7)     
         18.8(10.8)  
        
 
 
         27.4 (13.5)    
         13.1  (4.1)    
         14.1  (10.5) 
Follow-up                                    19.0(12.3)          11.7(6.9)          13.4(6.1) 
GENERAL  
Main measures                      
 
Hospitalization starts 
Hospitalization ends  
5 month after discharge 
       
 
 
       43.2(9.5)             
       33.7 (5.7) 
       34.1 (8.0) 
        
 
 
         46.5(10.5)  
         34.6(12.8)   
         31.6(9.7) 
 
 
        
 
         48.9(8.3)    
         31.8(8.9)      
         30.4(10.1)  
 
Follow-up                                   27.2(9.5)          26.0(12.0)          25.9(8.3) 
TOTAL 
Main measures                      
 
Hospitalization starts 
Hospitalization ends 
5 month after discharge  
     
 
      
      88.0(19.2)   
      66.9 (11.9)  
      65.1 (15.1)   
 
       
 
 
         90.4(19.3) 
         62.9(22.2)   
         61.1(18.8) 
 
  
 
 
          97.7(23.9)    
          66.5(13.2) 
          58.1(22.7) 
 
Follow-up                                     59.0(24.5)                     48.3(18.5)          49.9(13.3) 
DOSE HALOPERIDOL 
equivalents (mg/day) 
  
      
 
 
 
      
Main measures                     
 
Long term Follow-up       
 
    13.2   (8.4)   
 
    17.6  (5.4)  
          4.3    (2.4) 
 
          8.3   (7.3) 
        10.3  (6.6) 
 
        13.2  (7.5) 
Results presented as mean (standard deviation). For  Main measures N=58:  Conventional N=19; Atypical 
N=21; Clozapine N=16; A Follow-up N= 24: Conventional N=5; Atypical N=7; Clozapine N=12  
Table 3. PANSS changes over time in relation to antipsychotic medication and dose of 
haloperidol equivalents (mg/day) in schizophrenics patients 
www.intechopen.com
 
Mental Illnesses – Understanding, Prediction and Control 
 
214 
   ToM Tasks                           Discharge                   Follow-up  
                                                   N=58                              N=24 
First-Order ToM Tasks       
Category 0 + Category 1         (N=12) 11.9   (8.0)       (N=4)  14.3  (8.3) 
Category 2                                 (N=46) 7.3   (6.7)        (N=20) 13.2  (8.1) 
 
p value                                       U=190.500  
                                                    p=0.009* 
Second-order ToM Tasks       
Category 0+ Category  1       (N=20) 10.4    (7.1)         (N=5)  17.8   (5.1) 
Category 2                               (N=38)   7.5    (7.4)        (N=19) 13.3   (8.4) 
 
p value                                       U=276.000  
                                                   p=0.052 
Results are presented as mean (standard deviation) of mean dosage of haloperidol equivalents. Analysis 
of distribution between ToM tasks categories with mean dosage of haloperidol at discharge were 
carried out with the Mann-Whitney test; *p<0.05 level of significance 
Table 4. Relations between first- and second-order ToM tasks performance and mean dosage 
of haloperidol equivalents at discharge and follow-up of the schizophrenia group 
 
 
 
*Conventional (non-refractory patients): mixed antipsychotic group is included within this group.  
Percentage of good performance at ToM tasks were: conventional 26.8%, atypical 30.4% and clozapine 
21.4%; (X2=0.194; p=0.908).  
(a) 
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*Conventional (non-refractory patients): mixed antipsychotic group is included within this group.  
Percentage of good performance at ToM tasks were: conventional 12.5%, atypical 25.0% and clozapine 
45.8%. 
(b) 
Fig. 1. (a) Antipsychotic treatment type and first-order ToM tasks at discharge study  
(b) Antipsychotic treatment type and first-order ToM tasks at the long term follow-up in a 
subsample of the schizophrenia patients  
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*Conventional (non-refractory patients): mixed antipsychotic group is included within this group. 
Percentage of good performance ToM tasks were: conventional 19.1%, atypical 28.6%  and clozapine 
16.1% ; (X2=2.084; p=0.353)  
(a) 
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*Conventional (non-refractory patients): mixed antipsychotic group is included within this group.  
Percentage of good performance ToM tasks were: conventional 12.5%, atypical 25.0% and clozapine 
41.7%.   
(b) 
Fig. 2. (a) Antipsychotic treatment type and second-order ToM tasks at discharge study  
(b) Antipsychotic treatment type and second-order ToM tasks at the long term follow-up in 
a subsample of the schizophrenia patients  
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Regression 
coefficient 
95% Confidence 
interval 
p-value 
Threshold [ToM1 = 0] -3.225 (-4.700; -1.750) <0.001 
Threshold [ToM1 = 0] -2.667 (-4.057; -1.278) <0.001 
PAS: Social isolation -1.990 (-3.754; -0.227) 0.027 
Trail B -0.009 (-0.016; -0.001) 0.026 
Males -0.385 (-1.357; 0.586) 0.586 
The link function applied was the probit link. Pseudos R-square values amounted to: 0.224   
(Cox and Snell); 0.300 (Nagelkerke); and 0.184 (McFadden). 
Table 5a. Regression coefficients of an ordinal model to explore the relative weight of first 
order ToM tasks at predicting treatment resistance factors including premorbid adjustment 
(social isolation), trail B and gender as explanatory variables 
 
 
Regression 
coefficient 
95% Confidence 
interval 
p-value 
Threshold [ToM2 = 0] -5.975 (-12.251; 0.300) 0.062 
Threshold [ToM2 = 0] -0.317 (-4.673; 4.040) 0.887 
PAS: Social isolation -14.003 (-26.340; -1.666) 0.026 
Blocks design 0.291 (0.033; 0.549) 0.027 
Clozapine -3.379 (-6.734; -0.025) 0.048 
Males -5.580 (-10.775; -0.385) 0.035 
The link function applied was the Cauchy link. Pseudos R-square values amounted to: 0.551 (Cox and 
Snell); 0.657 (Nagelkerke); and 0.440 (McFadden). 
Table 5b. Regression coefficients of an ordinal model to explore the relative weight of 
second-order ToM tasks at predicting treatment resistance factors including premorbid 
adjustment (social isolation), blocks design, clozapine and gender as explanatory variables 
4. Discussion  
This study identified distinctive responses on ToM performance with different antipsychotic 
medications in stable schizophrenics: initially patients responded relatively better with 
atypical antipsychotics in contrast to clozapine and conventional agents. Nevertheless, over 
time clozapine provided some hints of better restoration of mentalizing abilities than other 
antipsychotics agents. Also, the findings confirmed predictors of unfavourable response to 
antipsychotic treatment in patients with poor mentalizing deficits. These predictors include 
male gender, social isolation (poor premorbid adjustment), low performance in block design 
and receiving clozapine treatment at start higher severity. That constellation of factors 
characterized a well-studied subgroup of patients having a poor prognosis. Cohering with 
previous findings, the present sample of stabilized schizophrenia outpatients showed 
difficulties across diverse interpersonal functions in contrast to healthy controls: they were 
mainly less independent, with no children, and either unemployed or disabled.  Decreased 
premorbid adjustment across age epochs in which full-blown schizophrenia symptoms 
appear has also been found in other studies (Strous et al., 2004; Vourdas et al., 2003). 
Schizophrenic patients performed worse than control group on both first and second order 
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ToM tasks, without differences in intelligence quotient measures. Regarding the links 
between ToM performance and antipsychotic medication, the results showed drug’s 
positive effects on mentalizing abilities with a tendency to increase over the years in the 
restricted subsample re-examined at follow-up meaning perhaps that the deficits in social 
cognitive abilities were relatively restored over the long-term. After discharge the patients 
who had been prescribed atypical antipsychotic drugs displayed a modest superiority on 
mentalizing skills in contrast with those receiving conventional antipsychotic or clozapine. 
Almost a decade later, in the follow-up, clozapine showed a modest trend of better efficacy, 
despìte that at least a fraction of those patients were highly resistant to treatment and 
showed deep second-order mentalizing handicaps when first studied at the start of the 
study.This trend may cohered with Savina and Berninger (2007) findings, showing that 
clozapine (and olanzapine) improves ToM abilities due to the enhancement of mPFC 
function, although they measured that over the short-term. Dosage of antipsychotic was 
lower in patients with good performance on mentalizing skills, indicating less illness 
severity.  
The accumulating evidence suggests that improvement in cognitive function might be 
expected to follow reduction of psychotic symptoms, with differences between 
antipsychotics at improving cognitive performance, being rather modest and never 
normalizing cognitive function (Barnes, 2011; Lieberman et al., 2005).  Also, the literature 
suggests a parallel path for both atypical antipsychotics in non-resistant patients and 
clozapine in resistant ones at improving psychosis and cognition deficits (O’Carroll, 2000; 
Keefe and Fenton, 2007). It is worth noting that clozapine treatment remains as one of the 
most effective for schizophrenia and consensus treatment guidelines from a wide range of 
prominent expert panels specify that (APA, 2004; Goodwin et al., 2009; NICE, 2010), 
recommending its use after the failure of 2 adequate trials with other antipsychotics, 
including an atypical one, to get adequate response or in patients with persistent suicidal 
gestures or ideation. So it would be desirable to introduce clozapine in appropriate time and 
dosages (Joober and Boksa, 2010), to improve social cognitive abilities as well as to enhance 
pro-social function (Toua et al., 2010; Möller et al., 2011).  
Concerning disease state at baseline, before treatment commencement, it is important to 
highlight that second-order ToM tasks deficits disclosed well-characterized factors related 
with poor prognosis: male gender, (Caspi et al., 2007), poor premorbid functioning (Duñó et 
al., 2008; Strous et al., 2004) and executive functioning deficits, specifically  planning and 
coordination dysfunction (Béchard-Evans et al., 2010; Koelkebeck et al., 2010; Rabinowitz et 
al., 2000), together with particular drug regimes (clozapine) required to achieve a quick 
clinical stabilization (Barnes, 2011). Severe deficits in social cognition have been repeatedly 
shown along these factors (Duñó et al., 2008; Montreuil et al., 2010; Schenkel et al., 2005; 
Uhlhaas and Silverstein 2005). It is interesting to note that mentalizing deficits had not been 
previously described as a predictor factor of poor response to treatment. Therefore it is 
important to note that refractory responses to drug treatment ought to be expected in 
patients with poor mentalizing skills especially if they are accompanied with these factors of 
poor outcome.  
This study had obvious limitations. The ToM tasks employed, although widely used in the 
literature, have not been fully validated. The study characterized a substantial homogeneous 
sample, but at the long term follow-up study half of the sample did not accept to collaborate 
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again thus restricting the weight of those results. In conclusion, our findings reflect 
beneficial effects of antipsychotic agents at restoring ToM ability, especially clozapine, in a 
sample of stabilized schizophrenics. Also we found second-order ToM tasks deficits as a 
predictor factor of poor response to antipsychotic treatment together with others well 
described in the literature: male gender, poor premorbid adjustment, executive dysfunctions 
(coordination-planning) and clozapine at baseline (higher clinical severity).       
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